Department of Surgery, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
J Vasc Surg. 2011 Nov;54(5):1259-65; discussion 1265. doi: 10.1016/j.jvs.2011.03.301. Epub 2011 Jul 29.
To determine the outcome of endovascular therapy for an infected aortic aneurysm in patients with or without aorto-aerodigestive/aortocaval fistulas.
From September 2005 to May 2010, 21 patients, 17 abdominal and four thoracic infected aortic aneurysms were treated with an endovascular stent graft at Songklanagarind Hospital, Thailand. Five patients presented with fistula complications, 1 aortoesophageal, 1 aortobronchial, 1 aortocaval, and 2 aortoenteric fistulas. Lifelong antibiotics were planned for all patients. In-hospital mortality and follow-up outcomes were examined.
The average age was 66 years (range, 42-84) and 18 patients were male. All five cases in the fistulous group presented with symptoms related to the organs involved, four massive bleedings and one congestive heart failure. Symptoms of patients in the nonfistulous group were abdominal, back, or chest pain in 94%, fever in 81%, and diarrhea in 19%. Blood culture was positive in 10 patients (48%): eight Salmonella spp and two Burkholderia pseudomallei. The overall in-hospital mortality was 19% (4/21): 60% (3/5) in the fistula group and only 6% (1/16) in the nonfistula group. One conversion to open repair was performed in the fistula group 2 weeks after the endovascular procedure. During the follow-up period, one of the two survivors in the fistula group died at 18 months from unrelated causes, while there were no deaths in the 15 patients of the nonfistula group with an average patient follow-up of 22 months (range, 1-54). Periaortic inflammation and aneurysms in the nonfistula group completely disappeared in 10 of the 15 patients (67%). The aneurysm significantly shrunk in four patients (27%), and was stable at 1 month in one patient. There were no late conversions.
Endovascular therapy, as a definite treatment for infected aortic aneurysms, provided excellent short- and medium-term results in patients without fistula complications. However, a poorer outcome was evident in patients with fistula complications.
确定血管内治疗伴或不伴主动脉-消化/主动脉-腔静脉瘘的感染性主动脉瘤患者的结局。
2005 年 9 月至 2010 年 5 月,在泰国宋卡王子大学医院,对 21 例 17 例腹主动脉和 4 例胸主动脉感染性主动脉瘤患者采用血管内支架移植物进行治疗。5 例患者出现瘘管并发症,其中 1 例为主动脉-食管瘘,1 例为主动脉-支气管瘘,1 例为主动脉-腔静脉瘘,2 例为主动脉-肠瘘。所有患者均计划接受长期抗生素治疗。检查住院死亡率和随访结果。
平均年龄为 66 岁(范围,42-84 岁),18 例为男性。瘘管组 5 例患者均出现与受累器官相关的症状,其中 4 例大出血,1 例充血性心力衰竭。非瘘管组患者的症状为 94%的腹痛、背痛或胸痛,81%的发热和 19%的腹泻。10 例(48%)血培养阳性:8 例为沙门氏菌属,2 例为类鼻疽伯克霍尔德菌。总的院内死亡率为 19%(4/21):瘘管组 60%(3/5),非瘘管组 6%(1/16)。瘘管组中有 1 例患者在血管内手术后 2 周内转为开放修复。在随访期间,瘘管组的 2 名幸存者中有 1 人在 18 个月时死于非相关原因,而非瘘管组的 15 名患者中无死亡,平均随访时间为 22 个月(范围,1-54 个月)。非瘘管组 15 例患者中有 10 例(67%)的主动脉周围炎症和动脉瘤完全消失。4 例患者(27%)的动脉瘤明显缩小,1 例患者在 1 个月时稳定。无晚期转换。
血管内治疗作为感染性主动脉瘤的明确治疗方法,在无瘘管并发症的患者中提供了极好的短期和中期结果。然而,有瘘管并发症的患者预后较差。